West Pharmaceutical Q3 2026 diluted EPS jumps 57% year on year to $3.02
Bitget2026/10/29 10:05- West Pharmaceutical Services’ third-quarter 2026 diluted EPS jumped 57% year over year to $3.02.
- Net sales rose 9% year over year to $874.5 million, led by High-Value Product Components.
- Stock repurchases totaled $231 million in the quarter, bringing the year-to-date total to $685 million.
- Full-year 2026 diluted EPS guidance stands at $9.31 to $9.41.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
SoftBank develops contingency plans for slowdown in US data center business, considers shifting to other countries
A new twist has emerged in the US AI data center investment boom. SoftBank is preparing for cooling US demand and a deteriorating political environment, and does not rule out shifting data center construction priorities to other countries. As cross-border computing power delivery capability improves and investment returns come under question, the logic behind AI infrastructure expansion is loosening, and over $3.5 trillion in infrastructure investment now faces potential impairment risks.
Quantumrail Cancels 10 Billion Won Convertible Bond Offering
Crypto prices
More
